Back to Journals » Journal of Asthma and Allergy » Volume 14

Allergen Immunotherapy: Biomarkers and Clinical Outcome Measures

Authors Pitsios C

Received 2 December 2020

Accepted for publication 27 January 2021

Published 18 February 2021 Volume 2021:14 Pages 141—148


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Luis Garcia-Marcos

Constantinos Pitsios

Allergy Outpatient Clinic, Medical School, University of Cyprus, Nicosia, Cyprus

Correspondence: Constantinos Pitsios
Allergy Outpatient Clinic, Medical School, University of Cyprus, P.O. Box 20537, Nicosia, 1678, Cyprus
Tel +30 6974348638
Fax +357 22 895396

Abstract: Clinical trials for allergen immunotherapy products’ development and approval are conducted, aiming to monitor safety and efficacy of them. Symptom scores and the use of rescue medication are the primary clinical endpoints used in the conducted clinical trials, while Quality of Life scores and symptom-free days are measurements also used as secondary endpoints. Although the use of in vitro biomarkers might have been more practical and objective, there are yet no broadly used reliable ones accurately reflecting the clinical effects of allergen immunotherapy. On the contrary, in vivo biomarkers, such as the nasal allergy provocation test, are reliable and successfully used. The aim of this review is to describe how to adapt and use biomarkers and clinical outcomes in the everyday practice of Allergists who perform allergen immunotherapy.

Keywords: allergic immunotherapy, clinical trials, allergic rhinitis, asthma, biomarkers

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]